Cargando…

Role of Pharmacogenetics in the Treatment of Acute Myeloid Leukemia: Systematic Review and Future Perspectives

Acute myeloid leukemia (AML) is a heterogeneous disease characterized by remarkable toxicity and great variability in response to treatment. Plenteous pharmacogenetic studies have already been published for classical therapies, such as cytarabine or anthracyclines, but such studies remain scarce for...

Descripción completa

Detalles Bibliográficos
Autores principales: Pinto-Merino, Álvaro, Labrador, Jorge, Zubiaur, Pablo, Alcaraz, Raquel, Herrero, María José, Montesinos, Pau, Abad-Santos, Francisco, Saiz-Rodríguez, Miriam
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8954545/
https://www.ncbi.nlm.nih.gov/pubmed/35335935
http://dx.doi.org/10.3390/pharmaceutics14030559
_version_ 1784676119633461248
author Pinto-Merino, Álvaro
Labrador, Jorge
Zubiaur, Pablo
Alcaraz, Raquel
Herrero, María José
Montesinos, Pau
Abad-Santos, Francisco
Saiz-Rodríguez, Miriam
author_facet Pinto-Merino, Álvaro
Labrador, Jorge
Zubiaur, Pablo
Alcaraz, Raquel
Herrero, María José
Montesinos, Pau
Abad-Santos, Francisco
Saiz-Rodríguez, Miriam
author_sort Pinto-Merino, Álvaro
collection PubMed
description Acute myeloid leukemia (AML) is a heterogeneous disease characterized by remarkable toxicity and great variability in response to treatment. Plenteous pharmacogenetic studies have already been published for classical therapies, such as cytarabine or anthracyclines, but such studies remain scarce for newer drugs. There is evidence of the relevance of polymorphisms in response to treatment, although most studies have limitations in terms of cohort size or standardization of results. The different responses associated with genetic variability include both increased drug efficacy and toxicity and decreased response or resistance to treatment. A broad pharmacogenetic understanding may be useful in the design of dosing strategies and treatment guidelines. The aim of this study is to perform a review of the available publications and evidence related to the pharmacogenetics of AML, compiling those studies that may be useful in optimizing drug administration.
format Online
Article
Text
id pubmed-8954545
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-89545452022-03-26 Role of Pharmacogenetics in the Treatment of Acute Myeloid Leukemia: Systematic Review and Future Perspectives Pinto-Merino, Álvaro Labrador, Jorge Zubiaur, Pablo Alcaraz, Raquel Herrero, María José Montesinos, Pau Abad-Santos, Francisco Saiz-Rodríguez, Miriam Pharmaceutics Review Acute myeloid leukemia (AML) is a heterogeneous disease characterized by remarkable toxicity and great variability in response to treatment. Plenteous pharmacogenetic studies have already been published for classical therapies, such as cytarabine or anthracyclines, but such studies remain scarce for newer drugs. There is evidence of the relevance of polymorphisms in response to treatment, although most studies have limitations in terms of cohort size or standardization of results. The different responses associated with genetic variability include both increased drug efficacy and toxicity and decreased response or resistance to treatment. A broad pharmacogenetic understanding may be useful in the design of dosing strategies and treatment guidelines. The aim of this study is to perform a review of the available publications and evidence related to the pharmacogenetics of AML, compiling those studies that may be useful in optimizing drug administration. MDPI 2022-03-03 /pmc/articles/PMC8954545/ /pubmed/35335935 http://dx.doi.org/10.3390/pharmaceutics14030559 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Pinto-Merino, Álvaro
Labrador, Jorge
Zubiaur, Pablo
Alcaraz, Raquel
Herrero, María José
Montesinos, Pau
Abad-Santos, Francisco
Saiz-Rodríguez, Miriam
Role of Pharmacogenetics in the Treatment of Acute Myeloid Leukemia: Systematic Review and Future Perspectives
title Role of Pharmacogenetics in the Treatment of Acute Myeloid Leukemia: Systematic Review and Future Perspectives
title_full Role of Pharmacogenetics in the Treatment of Acute Myeloid Leukemia: Systematic Review and Future Perspectives
title_fullStr Role of Pharmacogenetics in the Treatment of Acute Myeloid Leukemia: Systematic Review and Future Perspectives
title_full_unstemmed Role of Pharmacogenetics in the Treatment of Acute Myeloid Leukemia: Systematic Review and Future Perspectives
title_short Role of Pharmacogenetics in the Treatment of Acute Myeloid Leukemia: Systematic Review and Future Perspectives
title_sort role of pharmacogenetics in the treatment of acute myeloid leukemia: systematic review and future perspectives
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8954545/
https://www.ncbi.nlm.nih.gov/pubmed/35335935
http://dx.doi.org/10.3390/pharmaceutics14030559
work_keys_str_mv AT pintomerinoalvaro roleofpharmacogeneticsinthetreatmentofacutemyeloidleukemiasystematicreviewandfutureperspectives
AT labradorjorge roleofpharmacogeneticsinthetreatmentofacutemyeloidleukemiasystematicreviewandfutureperspectives
AT zubiaurpablo roleofpharmacogeneticsinthetreatmentofacutemyeloidleukemiasystematicreviewandfutureperspectives
AT alcarazraquel roleofpharmacogeneticsinthetreatmentofacutemyeloidleukemiasystematicreviewandfutureperspectives
AT herreromariajose roleofpharmacogeneticsinthetreatmentofacutemyeloidleukemiasystematicreviewandfutureperspectives
AT montesinospau roleofpharmacogeneticsinthetreatmentofacutemyeloidleukemiasystematicreviewandfutureperspectives
AT abadsantosfrancisco roleofpharmacogeneticsinthetreatmentofacutemyeloidleukemiasystematicreviewandfutureperspectives
AT saizrodriguezmiriam roleofpharmacogeneticsinthetreatmentofacutemyeloidleukemiasystematicreviewandfutureperspectives